MiMedx Group, Inc. (MDXG)
NASDAQ: MDXG · Real-Time Price · USD
4.588
-0.052 (-1.12%)
At close: Oct 2, 2026, 4:00 PM EDT
4.590
+0.002 (0.04%)
After-hours: Oct 2, 2026, 4:10 PM EDT
MiMedx Group Revenue
MiMedx Group had revenue of $64.36M in the quarter ending June 30, 2026, a decrease of -34.73%. This brings the company's revenue in the last twelve months to $355.17M, down -2.36% year-over-year. In the year 2025, MiMedx Group had annual revenue of $418.63M with 19.99% growth.
Revenue (ttm)
$355.17M
Revenue Growth
-2.36%
P/S Ratio
1.89
Revenue / Employee
$439,571
Employees
808
Market Cap
668.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 418.63M | 69.75M | 19.99% |
| Dec 31, 2024 | 348.88M | 27.40M | 8.52% |
| Dec 31, 2023 | 321.48M | 53.64M | 20.03% |
| Dec 31, 2022 | 267.84M | 25.82M | 10.67% |
| Dec 31, 2021 | 242.02M | -6.22M | -2.50% |
| Dec 31, 2020 | 248.23M | -51.02M | -17.05% |
| Dec 31, 2019 | 299.26M | -59.86M | -16.67% |
| Dec 31, 2018 | 359.11M | 37.97M | 11.82% |
| Dec 31, 2017 | 321.14M | 99.43M | 44.85% |
| Dec 31, 2016 | 221.71M | 34.42M | 18.38% |
| Dec 31, 2015 | 187.30M | 69.07M | 58.43% |
| Dec 31, 2014 | 118.22M | 59.04M | 99.77% |
| Dec 31, 2013 | 59.18M | 32.13M | 118.76% |
| Dec 31, 2012 | 27.05M | 19.29M | 248.60% |
| Dec 31, 2011 | 7.76M | 6.97M | 883.74% |
| Dec 31, 2010 | 788.87K | - | - |
| Mar 31, 2009 | - | - | - |
| Mar 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Zevra Therapeutics | 136.07M |
| Wave Life Sciences | 65.37M |
| OmniAb | 38.46M |
| DBV Technologies | 5.04M |
| Shattuck Labs | 1.00M |
| Silence Therapeutics | 615.00K |
MDXG News
- 9 days ago - MiMedx announces ‘favorable’ federal court ruling on Axiofill - TheFly
- 9 days ago - MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter - GlobeNewsWire
- 24 days ago - MIMEDX to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - MiMedx price target raised to $8 from $6 at Craig-Hallum - TheFly
- 2 months ago - MiMedx price target raised to $7 from $5 at Lake Street - TheFly
- 2 months ago - MiMedx to acquire Sanara MedTech for $35 per share, $350M enterprise value - TheFly
- 2 months ago - MiMedx reports Q2 EPS (5c), consensus (3c) - TheFly
- 2 months ago - MiMedx Group Earnings Call Transcript: Q2 2026 - Transcripts